Development of Chiral Bisphosphine Ligands with a Terminal Olefin Enables Asymmetric Orthogonal Auto‐Tandem Catalysis
Angewandte Chemie International Edition · 2025-07 · 64 (27)
DOI: 10.1002/anie.202506881 ↗Kurz gefasst
Fachartikel in der Zeitschrift Angewandte Chemie International Edition, online erschienen am 25.04.2025. Verfasst von Dongyuan He und 9 weiteren Autor:innen. Beteiligte Einrichtung: Key Laboratory of Medicinal Chemistry for Natural Resource, Ministry of Education, School of Chemical Science and Technology, and State Key Laborator…. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 52 Literaturangaben. Gefördert von: National Natural Science Foundation of China, Yunnan Fundamental Research Projects, Project of Innovative Research Team of Yunnan Province.
Abstract (Originalsprache)
Auto‐tandem catalysis (ATC) leverages the multiple roles of the catalyst, facilitating the direct synthesis of complex molecules from simple starting materials in a highly efficient and step‐economical manner. However, in conventional ATC, employing a single catalyst imposes significant limitations on the variety of catalyzed reactions. Herein, we present a novel catalysis strategy termed “orthogonal auto‐tandem catalysis (OATC)”, which provides the unique opportunity to develop more efficient chemical transformations that cannot be achieved with existing catalytic modes. An unprecedented tandem annulation process involving four different catalytic cycles via asymmetric OATC is demonstrated. The enantio‐determining step is a previously unrealized Pd(0)‐catalyzed asymmetric allylic lactonization. The key to the whole success lies in the development of a new class of chiral bisphosphine ligands with a terminal olefin (TOPhos) that addressed not only the racemization issue of allylic ester products in classic π‐allylmetal chemistry, but also the inherent compatibility challenges in transition‐metal/organo dual catalytic system. Density functional theory (DFT) calculations unveil the vital role of the terminal olefin in TOPhos, enabling the differentiation of competitive enantioselective pathways.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Key Laboratory of Medicinal Chemistry for Natural Resource, Ministry of Education, School of Chemical Science and Technology, and State Key Laboratory for Conservation and Utilization of Bio-Resources in Yunnan, Yunnan…
- Tianjin Key Laboratory of Molecular Optoelectronic Sciences, Department of Chemistry, School of Science, Tianjin University, Tianjin, 300072, China.
- Southwest United Graduate School, Kunming, 650092, China.
- Shanghai Key Laboratory for Molecular Engineering of Chiral Drugs, Shanghai Jiao Tong University, Shanghai, 200240, China.
Förderung
- National Natural Science Foundation of China
- Yunnan Fundamental Research Projects
- Project of Innovative Research Team of Yunnan Province
- Yunnan Provincial Science and Technology Project at Southwest United Graduate School
- Open Research Fund of Shanghai Key Laboratory for Molecular Engineering of Chiral Drugs
- Postgraduate Research and Innovation Foundation of Yunnan University
Zitieren
APA
He, D., Xu, H., Cao, P., Li, L., Luo, Y., Mon, E. E., Peng, F., Li, L., Dang, Y., & Shao, Z. (2025). Development of Chiral Bisphosphine Ligands with a Terminal Olefin Enables Asymmetric Orthogonal Auto‐Tandem Catalysis. Angewandte Chemie International Edition, 64(27). https://doi.org/10.1002/anie.202506881
Vancouver
He D, Xu H, Cao P, Li L, Luo Y, Mon EE, et al. Development of Chiral Bisphosphine Ligands with a Terminal Olefin Enables Asymmetric Orthogonal Auto‐Tandem Catalysis. Angewandte Chemie International Edition. 2025;64(27). doi:10.1002/anie.202506881
BibTeX
@article{He2025,
author = {He, Dongyuan and Xu, Hui and Cao, Penglong and Li, Luqing and Luo, Youlian and Mon, Ei Ei and Peng, Fangzhi and Li, Long and Dang, Yanfeng and Shao, Zhihui},
title = {Development of Chiral Bisphosphine Ligands with a Terminal Olefin Enables Asymmetric Orthogonal Auto‐Tandem Catalysis},
journal = {Angewandte Chemie International Edition},
year = {2025},
volume = {64},
number = {27},
doi = {10.1002/anie.202506881}
}
EUVIMED